A Randomized, Double-Blind, Placebo-Controlled and Delayed-Start Study of LY3314814 in Mild Alzheimer's Disease Dementia (The DAYBREAK Study) Save

Date Added
August 23rd, 2016
PRO Number
Pro00057163
Researcher
David Clark

Silhouette
Keywords
Alzheimers, Dementia, Drug Studies
Summary

Subjects are being asked to volunteer for a research study because they have been diagnosed with Alzheimer's disease. Alzheimer's dementia is the most common form of dementia. It is a general term for memory loss and loss of other intellectual abilities that are serious enough to interfere with daily activities.

The purpose of this study is to see if the investigational drug, LY3314814 (study drug) can slow the progression of your Alzheimer's disease. In Part I of the study, subjects will either receive the study drug or placebo. After 78 weeks, all subjects will begin Part II where everyone is on the study drug.

Institution
MUSC
Recruitment Contact
John Keller
843-792-2209
kellej@musc.edu

A Phase 3 Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Aducanumab (BIIB037) in Subjects with Early Alzheimer's Disease Save

Date Added
September 8th, 2015
PRO Number
Pro00044560
Researcher
David Clark

Silhouette
Keywords
Alzheimers, Memory Loss
Summary

This study will be conducted in subjects with early AD, including subjects with mild cognitive impairment (MCI) due to AD and a subset of mild AD.

The purpose of this study is to find out whether (study drug) has the potential to be a helpful treatment that slows down disease progression in subjects with early Alzheimer's Disease (AD) by comparing it to placebo and to evaluate its safety (side effects), and to find out more about aducanumab.

The subject will have the option of participating in four sub-studies: DNA, positron emission tomography (PET), magnetic resonance imaging (MRI), cerebrospinal fluid (CSF) or the Long Term Extension study (LTE).

Study duration for each subject participating in the placebo-controlled period only will be approximately 102 weeks (up to an 8 week Screening Period, 76 weeks of placebo or aducanumab dosing, and 18 weeks of follow-up).

For subjects who enter the optional LTE, the total duration will be approximately 206 weeks or 47 months (up to an 8 week Screening Period, 76 weeks of placebo or aducanumab dosing, 4 weeks of follow-up, 100 weeks of dose-blind aducanumab dosing, and 18 weeks of follow-up).

Institution
MUSC
Recruitment Contact
Michele DeCandio
2-9016
decandio@musc.edu

Change_preferences

-- OR --

Create_login